The idea for BioIntraface (BI) began in late 2007, but our company was formally incorporated in the State of Rhode Island and Providence Plantations on February 12, 2009. BI has proprietary and patent pending platform technologies for metal oxide & polymer coatings wherein the specific properties of anti-bacterial activity, anti-inflammatory activity, anti-fibrotic activity, cellular adhesion can each be independently varied. BI is optimizing coatings for promising applications and will out-license specific formulations to industry leaders in those spaces.
Our primary management objective is to collaborate with academic researchers, clinicians, and medical device companies to further develop technology that will positively impact patients and lower the overall cost of medical treatment to the healthcare system. At this early point in the company, BI management is also in the process of raising sufficient funds (primarily non-dilutive) and creating appropriate processes and controls, all to facilitate this collaboration.